Key Takeaway: Alkermes plc has launched a Phase 2 study to assess ALKS 7290's safety and efficacy as an adjunctive treatment for major depressive disorder (MDD). This investigational drug targets orexin 2 receptors and is also being developed for ADHD. The study aims to evaluate its effectiveness alongside standard antidepressant therapies.
Market Sentiment Analysis
POSITIVE FACTORS
Initiation of Phase 2 study for ALKS 7290
Focus on major depressive disorder treatment
Potential adjunctive therapy to existing antidepressants
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+33%
120-day peak, hindsight
Typical move
3.1%
average across 10 past catalysts
Lead asset
ALKS 7290
Phase 2 · Attention Deficit Disorder With Hyperactivity (ADHD)
Full Press Release Details
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in adult participants with major depressive disorder (MDD). ALKS 7290 is the company’s investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD) and for the adjunctive treatment of MDD. “Orexin biology represents a compelling are
Frequently Asked Questions
What is ALKS 7290?
ALKS 7290 is an investigational orexin 2 receptor agonist developed by Alkermes.
What condition is ALKS 7290 targeting?
It targets major depressive disorder (MDD) as an adjunctive therapy.
What phase is the current study for ALKS 7290?
The current study is a Phase 2 clinical trial.
How does ALKS 7290 work?
ALKS 7290 works by targeting orexin 2 receptors to enhance antidepressant effects.